Is NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions?
Citations Over TimeTop 12% of 2013 papers
Abstract
Modulation of protein-protein interactions (PPIs) with small molecules has been hampered by a lack of lucid methods capable of reliably identifying high-quality hits. In fragment screening, the low ligand efficiencies associated with PPI target sites pose significant challenges to fragment binding detection. Here, we investigate the requirements for ligand-based NMR techniques to detect rule-of-three compliant fragments that form part of known high-affinity inhibitors of the PPI between the von Hippel-Lindau protein and the alpha subunit of hypoxia-inducible factor 1 (pVHL:HIF-1α). Careful triaging allowed rescuing weak but specific binding of fragments that would otherwise escape detection at this PPI. Further structural information provided by saturation transfer difference (STD) group epitope mapping, protein-based NMR, competitive isothermal titration calorimetry (ITC), and X-ray crystallography confirmed the binding mode of the rescued fragments. Our findings have important implications for PPI druggability assessment by fragment screening as they reveal an accessible threshold for fragment detection and validation.
Related Papers
- → Ligand specificity, privileged substructures and protein druggability from fragment-based screening(2011)49 cited
- → SEC-TID: A Label-Free Method for Small-Molecule Target Identification(2014)20 cited
- Fragment-based drug design: combining philosophy with technology.(2007)
- → Computational Methods to Support Fragment‐based Drug Discovery(2016)9 cited
- → Fragment Screening in Complex Systems(2016)1 cited